Kazuma Oyama MD
Interventional Cardiology, Cardiothoracic Imaging, Preventive Cardiology
Physician
Join to View Full Profile
60 Fenwood RoadBoston, MA 02115
Phone+1 617-732-5500
Dr. Oyama is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Tohoku University Faculty of MedicineClass of 2009
Publications & Presentations
PubMed
- 4 citationsEfficacy and Safety of Dapagliflozin According to Background Use of Cardiovascular Medications in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a...Kazuma Oyama, Itamar Raz, Avivit Cahn, Erica L Goodrich, Deepak L Bhatt
JAMA Cardiology. 2022-09-01 - 4 citationsBiomarker Prediction of Complex Coronary Revascularization Procedures in the FOURIER Trial.Antonio Fagundes Jr, David A Morrow, Kazuma Oyama, Remo H M Furtado, Thomas A Zelniker
Journal of the American College of Cardiology. 2022-08-30 - 12 citationsEffect of Evolocumab in Patients With Prior Percutaneous Coronary Intervention.Remo H M Furtado, Antônio Aurélio Fagundes Jr, Kazuma Oyama, Thomas A Zelniker, Minao Tang
Circulation. Cardiovascular Interventions. 2022-03-01
Press Mentions
Post-ACS Patients with Low LDL Levels Remain at Risk: IMPROVE-ITOctober 4th, 2021- Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV MedsJuly 27th, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
